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How Much Intellectual Property Protection Do the

Newest (and Coolest) Biotechnologies
Get Internationally?
Alix Weisfeld*

Since the completion of the Human Genome Project in 2000, we are
already seeing changes in health care. As we better understand the genetic basis
of disease, we are able to target therapies to these root causes of disease. This
paper will consider how two nascent areas of genetic medicine,
pharmacogenetics and biologics, interact with international intellectual property
("IP") law. Neither of these areas fits comfortably in the traditional intellectual
property model we use for pharmaceuticals. Due to their growing importance,
however, the implications for international law concerning these advances are
great.
The first section of the paper will give a background on what biologics and
pharmacogenetics are. Section II will examine regulatory protections given to
pharmaceuticals both nationally and abroad. Section III will consider what
patent protections have been awarded to pharmaceuticals in the US and
internationally. Section IV concludes.
I. WHAT ARE BIOLOGICS AND PHARMACOGENETICS,
AND WHO CARES?
A. WHAT ARE BIOLOGICS?
Biologics are drugs manufactured through biological processes. They are
some of the hottest drugs around today and are certainly among the most
expensive. Unlike chemical drugs, which typically are comprised of several
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hundred atoms, biologics are complex proteins that contain thousands of atoms
folded over onto themselves.' This structural complexity makes them much
more difficult to create, and consequently to duplicate.
Some biologics act as catalysts for biologic processes that subsequently
occur in the patient's body. A major example of this type of biologic is insulin.
Diabetics either do not make insulin properly or are desensitized to it, but
bacteria can be manipulated to produce human insulin when injected with the
human gene for insulin. Likewise, many vaccines are created by the biologic
process.
Other biologics, called monoclonal antibodies, interfere with the adhesion
of certain compounds to cell receptors. For example, rituximab is the generic
name for a monoclonal antibody that adheres to a particular molecule found on
the surface of the cells of abnormal B-cell lymphocytes that often occur in nonHodgkin's lymphoma. Rituximab binds to this molecule and causes the body to
destroy the cancerous cell. In addition to treating cancer, monoclonal antibodies
are useful for treating anemia, diabetes, hepatitis, and multiple sclerosis, and are
an effective growth hormone (which is often prescribed to prevent AIDS-related
wasting disease).
Because they are proteins and not chemicals, biologics must be
manufactured through living organisms. This makes them expensive to produce,
and consequently expensive for consumers.2 In 2001, 25 percent of all increases
in US hospital expenditures (which themselves account for 30 percent of all
medical expenses) were attributable to four products, three of which were
biologics (epoetin alfa, infliximab, and rituximab). Biologic sales in the US may
top $56 billion in 2006. 4

1
2

For a good overview of biologics, see Michael Kleinberg and Kristen Wilkenson Mosdell, Current
and Future Considerationsfor the New Classes of Biologicals, 61 Am J Health-Sys Pharmacy 695 (2004),
on which I relied heavily in this discussion.
Biologics are generally more expensive to produce than chemical-based medicines. See, for
example, Katja Feick, Patent Expiries and the Prospect of Cost Savings to Underline the Populariy of
Generics and Biogenetics in Europe, Business Briefing Pharmagenerics 2004 (2004), available online at
<http://bbriefings.com/pdf/955/ACFB3AC.pdf> (visited Sept 13, 2005).

3

Nilay D. Shah, et al, Projecting Future Drug Expenditures-2003, Am J Health-Sys Pharmacy (Jan 13,
2003), available online at <http://www.medscape.com/viewarticle/448268-1> (visited Nov 9,
2005). Kleinberg, et al, CMS, Office of the Actuary, National Health Statistics Group, June 2000.
Many of the world's most expensive drugs are biologics. Andrew Pollack, Biotech Drugs Face Patent
Challenges, San Jose Mercury News (Dec 28, 2000).

4

Some groups estimate that demand for biologics will increase in the US nearly 12 percent
annually. Biologics, The Freedonia Group (Nov 1, 2002), available online at <http://
www.marketresearch.com/map/prod/829707.html> (visited Sept 14, 2005).
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B. WHAT ARE PHARMACOGENETICS?
The term pharmacogenetics (commonly called "personalized medicine" in
the lay press), describes the process of targeting drug therapies to individual
patients' genetic make-up. Unlike biologics and chemical compounds, it is not a
drug product per se.
Pharmacogenetics aims to improve pharmaceutical safety and efficacy
based on genetic variation. This variation can occur in two ways. The first way
pharmacogenetics can be applied is to attack irregularities within the disease
itself (for example, drug-resistant strains of HIV or differences in tumor type). A
prominent example is Herceptin, which can effectively treat breast cancer, but
only works in about 25 percent of all women with the disease. Patients need to
be genetically screened before they are prescribed the medicine because there is
no other way to distinguish responders from non-responders.
The second way pharmacogenetics can be effective is when a patient's
genetic make-up affects interaction with a drug. Patients with asthma are a prime
example, since certain genetic haplotypes are more responsive to bronchospasm
drugs than others. Other areas where research has already begun to suggest
pharmacogenetic advances are Alzheimer's disease, pain management, and
depression.5
Depending on how a drug works, genetic differences in either the disease
or the patient can affect the safety and efficacy of the drug. These differences are
not insignificant; some researchers estimate these effects are shockingly
pervasive: as few as one-third of all drugs patients take may act as expected
when they are prescribed.6 The bad effects of a wrong prescription can be
severe. For example, there is wide variability in the reactions of patients to
asthma medication, so the same medicine can be an efficacious treatment for
one patient but result in dangerous side effects for another. Studies have found
that patients' genetic make-up is the source of much of this variation. A
prophylactic determination of how a patient is likely to respond to a particular
asthma drug can mean the difference between life and death. For some drugs,
side effects may not be obvious despite their negative effects on patient's health.

5

6

See PersonalMedicine: Welcome the Death of the Blockbuster Drug, Fin Times 20 (May 4, 2004); Andrew
Pollack, When Gene Sequencing Becomes a Fact of Lfe, NY Times C1 (Jan 17, 2001); Tom Abate, The
Economics of Genetic Testing, San Fran Chron G1 (Feb 10, 2002); Connie M. Drysdale, et al, Complex
Promoterand Coding Region Beta 2-Adreneqgic Receptor Haplojpes Alter Receptor Expression and Predict In
Vivo Reiponsiveness, 97 Proc Natl Acad Sci 10483 (2000).
Sophie Petit-Zelman, Hard to Swallow; If a PharmaceuticalGiant Casts Doubt on Whether Medicines
Work, Is It Worth Taking Them at All?, Irish Times 11 (Dec 22, 2003); Ronald M. Norton, Clinical
Pbarmacogenomics:Applications in PharmaceuticalR&D, 6 Drug Discovery Today 180 (Feb 2001).

7

Lyle J. Palmer, et al, PharmacogeneticsofAsthma, 165 AmJ Respir Crit Care Med 861 (2002).
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Pharmacogenetics' potential is limited by the fact that many diseases with a
genetic component, such as obesity, diabetes, coronary artery disease, and
depression, are complex. They are either multifactorial (the result of geneenvironment interactions) or polygenetic (the product of the interaction of many
genes). Although we currently have a solid understanding of how genetics affects
diseases when just a single genetic mutation results in a disease (examples
include Down's syndrome, cystic fibrosis, or Huntington's, all of which are
relatively rare), comprehension is less complete when we are dealing with more
complex (and prevalent) diseases that have a genetic component but are not
completely genetically determined. Nevertheless, even today, pharmacogenetics
can be a beneficial tool, particularly for diseases for which there is a lot of
variability in patients' responses to drugs. In these cases, it is difficult to observe
(without genetic tests) a patient's response to the drug, and there are not a lot of
substitute treatment options available that work well for everyone.' A prominent
disease that fits these parameters is cancer.
The health policy and economic implications of pharmacogenetics are
legion. At first blush, this technology appears to be bad for pharmaceutical
companies that will lose profits when blockbuster drugs are demonstrated to be
inefficacious or even harmful to certain populations. However, several opposing
arguments have been put forward. First, increased information about drugs'
usefulness may allow drugs that had been abandoned because they were too
unsafe for the general population to be resurrected for select populations. An
example might turn out to be the high-profile cases of Celebrex and Vioxx,
which may still be the best treatments for people with osteo-arthritis and a
history of gastrointestinal bleeding, for whom the increased risk of heart attack is
acceptable, although they are not the best option for the general population
given the other options available. If these subpopulations are not identified, the
drugs will be taken off the market and abandoned. Second, more targeted and
specific knowledge may make the process of development both faster and
cheaper, since drugs can be tested based on signaling molecules that have been
linked with the disease in humans. Third, marketing will also be more specific
and therefore less costly than the blanket ads that are necessary for
undifferentiated blockbusters.
Regulatory agencies, such as the Food and Drug Administration ("FDA")
in the US, require safety and efficacy data before they will approve a drug. As
information about who can take a particular drug becomes more significant,
these regulatory agencies will certainly require additional warnings on packaging.
It is possible they will also require genetic tests to be bundled with the drugs, in
8

Christopher R. Flowers and David Veenstra, The Role of Cost-Effectiveness Anaysis in the Era of
Phamacogenomics,22 Pharmacogenomics 481 (2004).
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order to emphasize the specificity of the drug's regulatory approval. 9 Some
health economists maintain these genetic tests may be a useful way for
governments and payers to ration expensive medications that will not benefit
patients (and may even harm them)," while others argue that the expense of the
genetic tests will be to prohibit the making of any population-wide changes in
how we prescribe most drugs. The loss of a segment of the American market
may also spur pharmaceutical companies to be even more interested in overseas
markets than they already are."
Whatever the long-term economic and health policy effects of these drugs
are, pharmacogenetic-based medicines are expected to become more and more
prevalent in the future. Pharmacogenetics almost certainly will result in the
development of thousands of variations targeted to specific subpopulations that
could never be developed under the traditional, "one size fits all" blockbuster
model.
C. THE OVERLAPPING RELATIONSHIP BETWEEN BIOLOGICS
AND PHARMACOGENETICS
Biologics are a subset of the broader category of pharmaceutical
substances, whereas pharmacogenetics describes the process of prescribing the
right drug to a particular patient. Sometimes, therefore, where a biologic drug
only works in people who have a certain genetic make-up, it may be prescribed
to a specific patient based on individual pharmacogenetic data. An example of
such a drug is Gleevec, a successful biologic that can eliminate certain kinds of
leukemia and stomach cancers. However, Gleevec only works in people whose
leukemia is associated with a genetic abnormality that is not shared by everyone
with the disease. Studies have found that people who do not have the particular
gene mutation that Gleevec treats do not respond well to the drug, while people
with the mutation had an 84 percent chance of a partial remission. 1 2 A simple

9
10

Rebecca S. Eisenberg, Will Pharmacogenomics Alter the Role of Patents in Drug Development, 3
Pharmacogenomics 571, 573 (2002).
Patricia Danzon and Adrian Towse, The Economics of Gene Therapy and ofPharmacogeneics,5 Value in

11

Health 5 (2002).
There are, of course, many other economic implications for pharmaceuticals, including raised

12

prices based on smaller demand and greater efficacy (quality), lower drug development costs as
clinical trials become more targeted, faster approval time by the FDA (and the subsequent
increased value of the patent), and potential application of the Orphan Drug Act (by which the
US government provides incentives for pharmaceuticals developing drugs that only benefit a
small population and that otherwise would not be viable). Although these topics are fascinating, I
will not focus on them here.
Michael C. Heinrich, et al, Kinase Mutaions and Imatinib Response in Paients With Metastatic
GastrointestinalStromal Tumor, 21 J of Clinical Oncology 4342 (2003).
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genetic lab test of a patient's bone marrow can be administered to determine if
the drug is appropriate.
D. WHY SHOULD WE CARE?
By all accounts, both biologics and pharmacogenetics will quickly and
steadily increase in importance during the coming decades.1 3 Both biologics and
pharmacogenetics have thus far had their biggest successes in diseases like
cancer and rheumatoid arthritis, which are primarily first world diseases.
Although the largest killers in the developing world (Africa, Asia, South
America) remain HIV/AIDS, tuberculosis, malaria, and respiratory infections,"
the potential demand for advances like pharmacogenetics and biologics in those
regions may still be great. Pharmacogenetic advances have implications for some
of these conditions, such as malaria, but this is still speculative. Biotechnologies
may not have much impact on sub-Saharan Africa at any time in the foreseeable
future, but other third world countries (including India and China) may have a
large demand for these drugs because of their growing middle classes. In middleincome countries, including much of Europe, the demand for these drugs is
large.
II. REGULATORY IP PROTECTIONS
A pharmaceutical company's IP is protected in two ways: by data
exclusivity provisions provided by the FDA and by patent laws. In the US, the
FDA imposes two requirements on any drug it approves: 1) it must be safe; and
2) it must be efficacious. Pharmaceutical companies must prove drugs meet both
these tests through the submission of data collected in clinical trials. The FDA
examines the data and, if it determines the benefits of the drug outweigh the
risk, the agency will allow the drug to be released to the public. In addition, the
FDA must approve the labeling of the drug and determine that the drug's
13

14

15

One reason for this is systemic-the current blockbuster drug model is simply untenable. The
statistics are staggering: only one in ten compounds ever reaches the market; each one costs, on
average, $897 million to develop; and more than 50 percent of compounds that are developed
cannot provide adequate returns on investment. Joseph A. DiMasi, Ronald W. Hansen, and
Henry G. Grabowski, The Price of Innovation: New Estimates of Drug Development Costs, 22 J Health
Econ 151 (2003). Of course, not all pharmaceuticals have such poor return on investment. Even
so, the potential for smaller-scale therapies (as are both pharmacogenetics and biologics) that may
be cheaper to develop because they are more specific is attractive to pharmaceutical companies,
and is a motivating factor behind the surge of research in both these areas.
Ellen 't Hoen, TRIPS, PharmaceuticalPatents, and Access to EssentialMedicines: A Long Way from Seattle
to Doba, 3 Chi J Ind L 27 (2002).
See Kenneth D. Vemick and Andrew P. Waters, Genomics and Malaria Control, 351 N Eng J Med
1901 (2004).
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manufacturing process sufficiently ensures purity. The FDA approval process is
generally accepted as the most rigorous in the world. 6 A drug that has been
approved by the FDA will certainly meet the safety and efficacy standards in
other nations, both developed and developing.
Data exclusivity, or the protection of proprietary information that
pharmaceutical companies submit as part of the FDA approval process, is an
important IP protection. It is explicitly provided by the regulatory agency and
not through the patent process.
The key issue raised by harmonization of drug approval processes involves
the exclusivity of information. The FDA requires a lot of data, data that are an
important proprietary asset worth billions of dollars to pharmaceutical
companies. Naturally, these companies are wary of passing this information on
to drug approval institutions that do not offer strong IP protections. In 1997,
the US and other developed nations-specifically, European Union members
and Japan-entered into Mutual Recognition Agreements ("MRAs"), in which
the countries agreed to work toward a system where reviews by one country
would be recognized by the other countries. 7 MRAs have less force than a
treaty, but are more than letter agreements. 8 A key requirement for the US in
these agreements was that data9 the FDA would protect would likewise be
shielded by the receiving nation.'
A. How Do BIOLOGICS FIT UNDER THE
REGULATORY SCHEME?
Biologics are complex molecules. Without access to proprietary
information, process conditions, and clinical trial data, it is very difficult to
replicate a biologic. Government regulatory agencies may also be concerned
about the difficulty in evaluating generic biologics.
Even if a nation's government regulatory agencies are not concerned,
developers face high purchase and maintenance costs for manufacturing and
storage facilities, which must keep the drug at precise temperatures. Although it
might be possible to manufacture and properly store a generic biologic, its
characteristics explain why generic equivalents are thus far not a major issue. In
16

17

18

See, for example, Linda Horton, Mutual Recognition Agreements and Harmonizalion, 29 Seton Hall L
Rev 692, 706 (1998).
The US/EU Mutual Recognition Agreement: The Medical Device Annex: Introduction, US Food and Drug
Admin, Center for Devices and Radiological Health (Apr 2, 2002), available online at <htrp://
www.fda.gov/cdrh/mra/introduction.html> (visited Sept 16, 2005).
James T. O'Reilly, Implications of InternationalDrugApproval Systems on Confidentiality of Business Secrets
in the US PharmaceuticalIndusty,53 Food Drug LJ 123, 123-24 (1998).

19

Id.
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the US, the FDA requires full clinical trials for every biologic even though, with
chemical compounds, an abbreviated new drug application (or approval process)
might suffice.2" This is because, with biologics, it is the process of manufacturing
that determines the end result.
Manufacturing generic biologics is not nearly as cost-advantageous as
traditional chemical pharmaceuticals because so much is embedded in the
process, and it is not clear that they could be offered at much lower prices than
the original biologics. In addition, this area of medicine is still changing so fast
that by the time a copycat biologic has come along, the developers of the
original may have already come out with a better version.
B. How Do PHARMACOGENETICS FIT UNDER OUR
REGULATORY SCHEME?

The exclusivity of information about drugs is particularly important to
manufacturers of drugs whose marketability is based on pharmacogenetics. It is
especially important when the patents on the drugs have already expired.
Typically, once a drug's patent has expired, the company will let it languish
because it is no longer valuable to invest in additional research. Generic
manufacturers can legally manufacture the drugs, free ride off the data collected
by the no longer protected initiating company, and sell the copycat drug on the
cheap. To encourage additional investment in already existing drugs, the HatchWaxman Act 21 includes a bioexclusivity provision to encourage investment in
research of new active ingredients by allowing originators to recoup the
considerable losses they incur in clinical trials. Under the Hatch-Waxman Act,
competitors are prohibited from using the data submitted by the originator of a
drug containing an active ingredient that had not previously been approved by
the FDA. After five years, competitors can use the data if they can demonstrate
bioequivalency with the originator's product. If these generic companies want
approval sooner, they have to obtain the data independently through their own
clinical trials.22 Data exclusivity may encourage drug companies to undertake
additional research (relying on pharmacogenetic technology) on drugs that
would otherwise fade into obscurity because they are no longer protected by a
patent.

20

Naomi Aoki, Generics Face Roadblocks in Copjing Biotech Drugs, Boston Globe D1 (Oct 31, 2001).

21

Drug Price Competition and Patent Term Restoration Act of 1984, Pub L No 98-417, 98 Stat

1585 (1984).
22

G. Lee Skillington and Eric M. Solovy, The Protectionof Test and Other Data Required by Article 39.3 of
the TRIPS Agreement, 24 NwJ Ind L & Bus 1, 10-12 (2003).

Vol. 6 No. 2

How Much IntellectualProperly Protection

Weiifeld

If, however, international regulatory bodies do not protect these data, the
benefit of data exclusivity will be eroded. For these drugs, there are no other IP
protections available.
III. PATENT PROTECTIONS
A. US IP LAWS
The US has a long history of strong patent protections. Article I, Section 8,
clause 8 of the Constitution states that Congress shall have the power "to
promote the Progress of Science and useful Arts, by securing for limited Times
to Authors and Inventors the exclusive Right to their respective Writings and
Discoveries., 23 The statutory grant of patent protection holds, "Whoever invents
or discovers any new and useful process, machine, manufacture, or composition
of matter, or any new and useful improvement thereof, may obtain a patent
therefore., 24 That is, patents can only be issued for inventions that are useful,
new, and nonobvious. In addition, the invention must fall into an identified
statutory category, such as processes, articles of manufacture and compositions
of matter.
Traditional pharmaceuticals are chemical compounds, and fall under the
compositions of matter heading. This category is the one most commonly
recognized by foreign laws and by international treaties. Neither biologics nor
pharmacogenetic products fit squarely within it.
B. BIOLOGICS AND PATENT PROTECTION IN THE US
Biologics that are exact replicas of naturally occurring substances are not
themselves patentable. Any patent involving biologics can be contentious,
because many people philosophically disagree with the notion that life can be
patented. Companies will seek patents for biologics after they make minor
modifications to a naturally occurring molecule, even though it is nearly identical
to the natural substance. In addition, in the US, manufacturers patent the cell
line used to develop the biologic. The US recognizes these patents (the landmark
case was Diamond v Chakrabary,2 in which the Supreme Court held man-made
microorganisms were patentable). Other countries, including European Union

23

US Const, art I, §8, d 8.

24

35 USC § 101 (2004).

25

447 US 303 (1980).
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members, who typically support strong patent protections, have moral
objections to the idea of patenting natural substances.2 6
In addition to cell line patents, manufacturers of biologics also obtain
process patents, which are allowed for the production of a nonobvious or novel
product. In 1995, Congress passed 35 USC § 103(b), which enables
manufacturers of biologics to avoid a review to determine whether the process is
nonobvious if it produces a nonobvious product.
C. PHARMACOGENETICS AND PATENT PROTECTION IN THE US
Before analyzing how pharmacogenetics will be covered by international
intellectual property law, we must first ask what, exactly, would be covered.
Many drugs associated with pharmacogenetics are traditional chemical or
biologic compounds, and as such can be patented in the same way traditional
pharmaceuticals are, based on their chemical compound or, if they are biologics,
with process patents. In addition to these, drug manufacturers can also seek
method-of-use patents in the US. 27 Method patents are obtained under 35 USC
§ 101 in the same way that machine patents are. However, they are not
universally accepted; more than eighty countries exempt medical method patents
from patent protection.28
But pharmacogenetic drugs, by definition, are bound up with genetic tests.
The tests, however, are protected separately from the drugs because they are
different things. The drug tests are patentable, even if the drugs that require
them are not. Genetic tests are patentable under both the "methods-of-use" and
"composition-of-matter" categories.2 9
D. INTERNATIONAL IP LAWS
International intellectual property law as it relates to pharmaceuticals has
been developed to balance: (1) efficacy; (2) safety; (3) quality; (4) access; and
26

27
28

29

Donna M. Gitter, InternationalConflicts over PatentingHuman DNA Sequences in the UnitedStates and the
European Union: An Arumentfor Compulsory Licensing and a Fair-UseExemption, 76 NYU L Rev 1623,
1625 (2001). A good example of moral objections making their way into public debate is the
European Parliament resolution on the patenting of BRCA1 and BRCA2 ("breast cancer") genes,
available online at <http://www.cptech.org/ip/health/biotech/eu-brca.html> (visited Sept 13,
2005), in which it "[r]eiterates its call on the European Patent Office 'to ensure that all... patent
applications in Europe do not violate the principle of non-patentability of humans, their genes or
cells in their natural environment."'
21 CFR § 314.53(b) (2004).
Robert M. Portman, Legislative Restnction on Medical and SurgicalProcedurePatents Removes Impediment to
Medical Progress,4 U Balt Intel Prop LJ 91, 98 (1996).
Bryn Williams-Jones, History of a Gene Patent: Tracing the Development and Appication of Commercial
BRCA Testing 10 Health LJ 123, 131 (2002).

Vol 6 No. 2

How Much Intellectual ProperyProtection

Weisfeld

(5) the incentive to invest in research. The first three of these five considerations
are largely issues of national policy carried out through governmental regulatory
agencies, which can (through their governments) be held responsible for any
violations of international law. The tension between the last two, however, is
evident in international law.
The application of international intellectual property law to traditional
pharmaceuticals is well-studied.30 Although bilateral trade agreements may
supersede multinational agreements, the most important source of intellectual
property protection is the World Trade Organization's Agreement on TradeRelated Aspects of Intellectual Property Rights ("TRIPS"), arts 27-34. In
general, member countries must provide patent protection for twenty years from
the date of filing the application, for both products and processes (but not
methods) .

This provision of TRIPS is supposed to enter into force completely in
2006. However, there are a number of "exceptions" to the basic rule that
threaten to swallow it whole, and may cast the value of the ostensible patent
protection into some doubt.3 2 Several exceptions have been justified by the
prototypical example for overriding patent protection: the need to provide lowcost H1V drugs to poverty-stricken countries. 33 However, only two have really
been effectively applied: Article 31's compulsory licensing and the parallel
importation and exhaustion of Article 28. The following are all potentially
relevant exceptions:
1. Article 31: Compulsory licensing, or use without authorization of the
right holder, such as in cases of national emergency or other circumstance
of extreme urgency.
Under Article 31, countries can manufacture a patented pharmaceutical
without the permission of the patent holder. In 2001, the WTO held the Doha
Round to clarify TRIPS. The Round produced the Doha Declaration, which
provides that countries have the right to issue compulsory licenses (allowing the
drugs to be manufactured in violation of the patent) and to determine "what
constitutes a national emergency or other circumstances of extreme urgency, it
being understood that public health crises, including those relating to

30
31

32
33

See, for example, Alan 0. Sykes, TRIPS, Pharmaceuicals,Developing Countries, and the Doha "Solution,"
3 ChiJ Intl L 47 (2002), and 'tHoen, 3 ChiJ Intl L at 27 (cited in note 14).
World Trade Organization, Agreement on Trade-RelatedAspects of IntellectualPropery Rights, Annex 1C
Agreement Establishing the World Trade Organization, arts 27(1) and 33 (1994), available online
at <http://www.wto.org/english/docse/legal-e/27-trips.pdf> (visited Sept 17, 2005).
Sykes, 3 Chi J Ind L at 49 (cited in note 30).
Pharmaceutical companies can overcome this problem by offering low-cost sales of certain drugs
to poor countries, of course, which in many cases they do.
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HIV/AIDS,",34tuberculosis, malaria and other epidemics, can represent a national
emergency.
2. Articles 6 and 28(1)(a): TRIPS' silence on the issue of parallel
the patent-holder over
importation, or the exhaustion of the rights of
35
products once they have entered another country.
Under Article 28, countries can "exhaust" or terminate the patent-holder's
rights after the initial sale into a country. The Doha Declaration provides that
"each Member [is] free to establish its own regime for such exhaustion without
challenge, subject to [nondiscrimination limitations]., 36 Exhaustion (which is
often called parallel importation) means that the patent-holder's control over a
product ends with the first sale of it into a country. In subsequent sales, he has
no control over how the product is sold. The result is that a poor country that
has negotiated to buy drugs at a low price can resell them to a richer country
where the price of the pharmaceutical, when bought directly from the patentholder, is higher. By declining to eliminate this practice, the Doha Declaration
and TRIPS are permitting parallel importation. This undermines the incentive to
pharmaceutical companies to provide low-cost drugs to poor countries, which in
turn creates a market for the drugs to be made elsewhere and sold cheaply to the
poor country, in violation of the patent-holder's intellectual property rights.
3. Article 27(2): Any inventions that negatively affect the ordre public or
morality, including human life or health.
This is a possible exception, but it has been interpreted to apply only to
"inventions dangerous to human, animal or plant life or health or seriously
prejudicial to the environment."3
4. Article 30: Limited exceptions to the rights conferred... taking account
of the legitimate interests of third parties.
Article 30, which allows nations to make limited exceptions to patents, has
not been raised, since overriding patent rights even for a proscribed period of
time would probably not constitute a "limited exception."3

34

World Trade Organization, Declaration on the TRIPS Agreement and Public Health, WTO Doc
WT/MIN(01)/DEC//2 5 (Nov 14, 2001) (emphasis added).

35

This category may be more of a trade issue than an intellectual property issue, but the World
Trade Organization's materials on intellectual property discuss it because of its implications for
the producer's ability to maintain control over its product.
W O, Declarationon TRIPS, WTO Doc WT/MIN(01)/DEC//2 at 5 (cited in note 34).

36

37
38

World Trade Organization, Overview: the TRIPS Agreement, available online
<http://www.wto.org/engish/tratop-e/trips.e/intel2-e.htm> (visited Sept 14, 2005).
Sykes, 3 Chi J Ind L at 52 (cited in note 30).
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E. BIOLOGICS UNDER TRIPS
Are biologics likely to be protected under the TRIPS framework? Before
answering this, we must ask whether biologics qualify for patent protection at all.
The functional similarity between biologics and traditional pharmaceuticalsboth of which treat health conditions-makes this an easy question; biologics do
qualify under TRIPS.
The next question is whether the popular Article 31 exception can be
invoked to override the process patents held by manufacturers of biologics. The
answer to that question is a resounding "no." The emergency provisions that
allow suspension of patent protection may be justified by the scourge of
epidemics like HIV, but are much harder to defend when the "epidemic" is
rheumatoid arthritis or cancer. Unlike HIV or other public health crises that
spread from person to person, the biologics that have been developed so far are
useful for diseases that are grounded at least partially in genetics. There is no
public health danger here because the market can still work efficiently in this
situation. Whether an affected individual takes the drug or not does not affect
the health and well-being of his neighbor, and therefore there is no public health
crisis, as the term was traditionally used. This is very different from, say,
tuberculosis, where if one person goes untreated, an entire community may be
infected.39 If, however, a biologic were discovered that dealt with a public health
crisis (say, for example, a vaccine for HIM, it would certainly fall under the
Article 31 exception. Thus far, however, biologics have not been developed for
pandemic conditions.
What about the issue of exhaustion under Article 28? Although parallel
importation has been all over the news in the US lately, the issue may be less
relevant for biologics than for traditional pharmaceuticals. 4 ° Like vaccines, which
are notorious for having to be thrown away because they have not been stored
properly, biologics are complex three-dimensional molecules, and their
properties must be carefully maintained not only at the time of manufacture but
also through proper storage.4 1 Biologics are therefore less viable candidates for
shipping back and forth, especially since any potential safety hazards will be
pounced upon by pharmaceutical companies' public relations teams as further
evidence that parallel importation leads to breakdowns in safety.42 In addition,
39

40
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For a useful discussion along this theme, see Richard A. Epstein, Let the Shoemaker Stick to His
Last:A Defense of the 'Old" PublicHealth, 46 Perspectives Biol Med S 138 (2003).
At this time, biologics are exempt from reimportation proposals in the US.
Kleinberg, et al, CMS, Office of the Actuary, National Health Statistics Group, June 2000 (cited in
note 3).
See, for example, Joel B. Finkelstein, Dnrg Import Crackdown Shows Hazards,American Med News 5
(Oct 25, 2004).
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many biologics have a limited shelf life, which means extensive shipping
becomes riskier.
Another reason parallel importation is less salient for biologics relates to
their patent type. In the US, biologics are covered by the Process Patents
Amendment Act of 1988. 43 Under the US Process Patent Amendments Act, it is
a violation to import, sell, or use within the US a product manufactured abroad
in violation of a US process patent. 44 US courts have said in dicta that
exhaustion does not apply to process patents, perhaps on the theory that
processes do not involve discrete steps in the same way that a sale does.4" The
law on this question is not entirely settled, however, and since the adoption of
the Process Patents Amendment Act in 1988, no buyer or seller has been held
directly liable under this provision.46 They have, however, been held liable for
indirect patent infringements. 47 Although this Act only applies in the US, this
country is one of the largest markets for imported drugs. TRIPS, of course,
makes no universal policy regarding exhaustion, and therefore individual
countries' laws apply.
Another possible exception particularly relevant to biologics is Article
27(3)(b), which exempts "biological processes for the production of plants or
animals other than non-biologicaland microbiologicalprocesses."48 Although the wording
might be somewhat ambiguous with regard to genetic material, it seems clear
that microbiological processes are not included in this exception, so they remain
protected. Moreover, reviews of the 27(3)(b) provisions did not mention
pharmaceuticals once. 41
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45
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Pub L No 100-418, 102 Stat 1563, codified at 35 USC § 295 (1988). This Act has been construed
to apply only to process patents that result in actual products (such as biologics), not the
production of data. See BayerAG v Housey Pharmaceuticals,Inc,340 F3d 1367 (Fed Cir 2003).
35 USC § 2 7 1 (g) (2004). The purpose of this statute is to prohibit the manufacture abroad of
products with a patented processes that can then be brought back to the US without violating the
patent.
Bandag Inc v Al Bolster's Tire Stores, Inc, 750 F2d 903, 924 (Fed Cir 1984) ("The doctrine that the
first sale by a patentee of an article embodying his invention exhausts his patent rights in that
article is inapplicable here, because the claims of the ... patent are directed to a 'method."').
Troy Peterson, U.S. Infringement Iabiliyfor ForeignSellers of InfringingProducts, 2003 Duke L & Tech
Rev 32 (2003).
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Ltdv Unison Industries, 899 F Supp 1268 (D Del 1995).
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animals other than non-biological and microbiological processes."
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F. PHARMACOGENETICS UNDER TRIPS
TRIPS article 27(3)(a) allows countries to exclude "diagnostic [or]
0
therapeutic... methods for the treatment of humans" from patent protection.
This provision will cover any method patents for pharmacogenetics, because any
such method patent will involve the diagnosis or treatment of people's health
care problems. Although genetic tests can be patented in the US, 5 the European
Patent Office recently limited a US company's patent on all diagnostic testing for
mutations in the BRCA1 and BRCA2 genes (which are associated with a higher
risk for breast and ovarian cancer) to "a probe of a defined composition for the
detection of a specific mutation in the breast and ovarian cancer susceptibility,"
and disallowed the patent for diagnostic methods.5 "
TRIPS is like the European law: diagnostic methods can be exempted from
protection under Article 27(3)(a). Although the drugs themselves are not
diagnostic, they are by definition implicitly, and at some point may be explicitly,
bundled with genetic testing capabilities.5 3 The question is whether the presence
of a bundled genetic test with the drug will overcome the protection granted to
the pharmaceutical. This seems unlikely because the two products are very
different; the test is given only once, whereas the drug may be taken for a
lifetime.
If the test is not considered a diagnostic method exempt from patent
protection, a question remains about whether pharmacogenetics can fall into the
Article 31 public health emergency exception. At this point, unlike retroviral and
similar HIV therapies, pharmacogenetic technologies do not treat acute
conditions for which there are no adequate substitute therapies available.
Instead, they tend to be for late-onset conditions, such as cancer and rheumatoid
arthritis. Although these conditions are devastating, they hardly constitute an
epidemic under Article 31.

online at <http://www.wto.org/english/tratop-e/trips_e/ipcw369_e.doc>
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Lori B. Andrews, The Gene Patent Dilemma: Balancing Commercal Incentives with Health Needs, 2002
Hous J Health L & Poly 65, 91-92. Professor Andrews also contends pharmaceutical companies
may patent genetic tests and then refuse to develop them, in order to keep patients from finding
out they should not take a drug. However, the potential liability for such practices, in addition to
all the other market forces that are encouraging the development of small-scale pharmacogenetics,
may weaken this argument.
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G. DATA EXCLUSIVITY
Another locus for pharmacogenetic protection under TRIPS is data
exclusivity. Even if the drug cannot be patented or its patent has expired, the
manufacturer might still be able to control proprietary information. 4 The data at
issue are the data submitted by the pharmaceutical company to a country's
regulatory approval organization (in the US, this is the FDA) regarding the
drug's safety and efficacy. If these data are protected, even if there is no patent
protection for a drug, the lack of data could conceivably function as a "partial
substitute for patent protection."" Article 1(2) of TRIPS provides that test data
qualify for protection as its own category of intellectual property. Article 39(3) of
TRIPS guarantees that countries whose regulatory agencies require data in order
to approve a "pharmaceutical ...which utilize[s] new chemical entities, the
submission of undisclosed test or other data, the origination of which involves a
considerable effort, shall protect such data against unfair commercial use."56
The major hurdle for manufacturers is that the data must be for a "new
chemical entity." The pharmacogenetic products seeking this type of protection
are not new at all; they are rehabilitated drugs that had been developed and
discarded, but now can be used to treat new indications.57 It would not make
sense to choose protection under Article 39(3) if the drug were still on patent
and there were other patent protections available. As one scholar put it, this type
of exclusivity is not "on the same footing as other intellectual property rights. In
particular, it cannot be inferred that such protection requires exclusive rights."58
This means plaintiffs may be granted remuneration, for example, but not the
right to prohibit the violation of their patents.59 The word "new" could be used
here to mean brand new or else "novel," in the traditional patent sense.
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See Clark G. Sullivan, How Personalized Medicine Is Changing the Rules of Drug Life Exclusivioy, 5
Pharmacogenomics 429 (2004), in which he argues the proprietary information contained on a
drug label about pharmacogenetic testing may prevent generic drugs from entering the market.
Note that patents and copyrights do not protect data itself. Rebecca Eisenberg, The Problem of New
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under some other provision of TRIPS (say, art 31). It is very unlikely that this would trump any
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Commentators disagree about which interpretation is preferable. 6 However,
since WTO member nations have discretion to choose whichever meaning they
prefer, it seems unlikely this avenue will be a profitable one for manufacturers.
Another exception under Article 39(3) is that manufacturers cannot keep
secret data necessary to protect the public. That means they cannot simply rely
on this provision to provide trade secret status (and give monopoly rents to
themselves) to information regarding who can benefit and who can be harmed
by the drug.6' And at any rate, this information is likely to be public anyway
through publication in scientific journals, especially if it relates to which patients
will benefit from the drug (and not its ingredients), and so it would already be
ineligible on those grounds.
H. METHOD-OF-USE PATENTS
The US recognizes method-of-use patents. These are particularly relevant
to drugs that have to be administered only to certain populations. However,
TRIPS does not explicitly call for protection of these patents.62 Moreover, these
patents are not infringed until someone actually uses the product (as when a
doctor prescribes it or a patient actually takes the drug), which means
governments cannot be held responsible for direct patent infringement.63 This
will make prosecution of these violations much more difficult and fact-intensive
and is not an optimal way for drug manufacturers to protect their property
interest.
IV. CONCLUSION
TRIPS is not radical for developed countries, since it basically tracks (or
may even be less protective than US) domestic intellectual property law. It is far
more significant for developing countries that have not established strong
internal intellectual property regimes. For these countries, the international
intellectual property protections biologics and pharmacogenetics receive seem
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inverted: biologics do not need them, but have them, while pharmacogenetics
need them, but do not have them.
Biologics are largely protected under existing international intellectual
property laws. But biologics are different from traditional chemical compounds
in an important way: the complex molecules must be manufactured in living
systems of one sort or another (mammalian, yeast, bacterial), and therefore they
must be essentially grown from scratch with living material and with great
precision each time they are made.6 4 Generic manufacturers (especially in
developing countries) may have difficulty acquiring the raw materials and
obtaining the precise conditions necessary for the delicate processes to occur.
The exceptions to this rule are Eastern European countries, China, and India, all
of which are capable of mastering the requisite complexity.
Without intellectual property limitations, the only restrictions on the
manufacture of generic biologics are safety, efficacy, quality, and economics.
Living organisms are more difficult to standardize than traditional chemical
compounds. For example, human growth hormone, one of the simplest
biologics to manufacture, is made by six companies, and each version is
different.6" Another frequently cited example is an anemia drug that was
manufactured by two different companies. One was fine, but the other had
serious efficacy and safety problems. Nobody was able to explain the
difference.66 Economic issues are more complex. Even cheap biologics are more
expensive than chemical drugs, and there may be limited markets because they
treat conditions most prevalent in developed countries.6"
Pharmacogenetic technologies, on the other hand, are afforded much less
IP protection. This is problematic from a public policy perspective: it is both
inefficient and inhumane not to invest in research designed to improve the way
we prescribe drugs to patients. The field of pharmacogenetics has economic
implications that differ greatly from traditional pharmaceutical products. It is
difficult to tell whether pharmacogenetic products will prove profitable for
manufacturers. It is even more difficult to assess the potential profitability of
generics. The main difference between pharmacogenetics and traditional
pharmaceuticals is that increased market segmentation may make the revenues
insufficient to cover fixed costs, rendering the drug not viable in the long run
(even with a price increase to reflect greater specificity). There is already a strong
64
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economic argument that the development of pharmacogenetics will erode the
large profits companies can extract for blockbuster drugs. Also, as was the case
in Vioxx, additional research into subpopulations can turn up disastrous data
that results in crippling liability. These fears discourage additional research in the
realm of pharmacogenetics. If pharmacogenetics are not provided with some
sort of intellectual property protections internationally, there is even less of an
incentive to invest in the field.
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